Adult T-cell leukemia-lymphoma (ATL) is a rare type of non-Hodgkin lymphoma caused by human T-lymphotropic virus type 1 (HTLV-1). 
Patients with acute-and lymphoma-type ATL, which are the major subtypes of ATL, accounting for approximately 80% of patients with ATL, have poor clinical outcome with 4-year overall survival (OS) rates of 11% and 16%, respectively. 5 Intensive chemotherapy is generally administered as first-line treatment for patients with aggressive ATL; however, allogeneic hematopoietic stem cell transplantation (HSCT) is thought to be the only potentially curable therapeutic option, provided the patient is deemed eligible. 5, 6 A recent nationwide survey in Japan revealed that the median age at diagnosis of ATL was 67.5 years, 7 which has been increasing over the past few decades, indicating that HTLV-1-infected individuals tended to be of an older age. 7, 8 Since most patients with ATL aged 70 years or older are ineligible not only for allogeneic HSCT 5,9 but also for dose-intensified cytotoxic chemotherapy, therapeutic options for patients with ATL aged ≥70 years are limited.
In 2012, mogamulizumab, a defucosylated humanized anti-CC chemokine receptor 4 (CCR4) monoclonal antibody, was first approved for the treatment of CCR4-positive relapsed or refractory (r/r) ATL in Japan, 10, 11 following which this postmarketing all-case surveillance study was initiated to evaluate its safety and effectiveness in clinical practice in Japan. The surveillance was mandated by the Pharmaceuticals and Medical Devices Agency in Japan, and data were collected prospectively from all patients who started mogamulizumab therapy during 1-year period after the launch. Preliminary safety information from the surveillance has been published in a previous report, 12 and the surveillance was completed in 2018, enrolling more than 500 patients with r/r ATL who were treated with mogamulizumab. Here, we report response rates, survival, and prognostic factors results from the postmarketing surveillance, together with the subset data of elderly patients with ATL in addition to updated safety information. 
| PATIENTS AND ME THODS

| Study design, patients, and treatment
| Safety and effectiveness evaluation
| RE SULTS
| Patient disposition and characteristics
Patient disposition is shown in Figure 1 . Data were collected from 577 of 597 patients, and 572 patients were included in the safety analysis population after excluding four unevaluable patients (three due to double enrollment and one due to no administration of mogamulizumab)
and one patient from a study site that did not provide consent for this publication. Of the 572 patients, 523 were included in the effectiveness analysis after excluding 49 patients due to either off-label use or unanalyzable data for effectiveness or both. Table 1 shows the characteristics of the safety analysis population. The majority of patients (93.8%) were of acute or lymphoma subtype, and in 30.8% of patients, mogamulizumab was used in combination with other modalities, mainly cytotoxic agents.
The median age of patients was 67.0 years, with patients aged ≥70 years accounting for 41.6% of the population. Following mogamulizumab treatment, 49 patients (8.6%) underwent allogeneic HSCT, of which 47 were aged <70 years. The median interval between the last mogamulizumab treatment and the HSCT was 36 days (range
6-191 days).
In the safety analysis population, the mean number of mogamulizumab administrations was 5.4, and 60% of patients did not complete all eight courses of mogamulizumab therapy, mainly due to disease progression (52.5%) and adverse events (37.0%).
| ADRs
As shown in (5.4% serious cases), pneumonia in 4.0% (3.3%), and sepsis in 2.3%
(1.9%) of patients. Other than these, CMV end-organ diseases such as CMV chorioretinitis, CMV enterocolitis, and CMV pneumonia were reported in 0.3% (2/572), 0.5% (3/572), and 0.3% (2/572) of patients, respectively. Of the 27 patients (25 serious cases) categorized as having immune system disorders, 25 patients (22 serious cases) were reported to have GVHD.
When these frequencies were stratified by ages of ≥70 and <70 years, no particular item was predominantly observed in the were aged <70 years in the surveillance. Of these 49 patients, 50.0%
(1/2) of patients aged ≥70 years and 42.6% (20/47) of patients aged <70 years experienced GVHD. Of patients experienced GVHD stratified by ages of ≥70 and <70 years, the median interval period between the last mogamulizumab treatment and the HSCT was 27 and 39 days (range 6-144), respectively.
| Response
The reported response rates are shown in reported to achieve CR, respectively. Among patients aged ≥70 vs <70 years, the best response rates were 57.9% vs 57.8%, respectively, and the response rates at the end of therapy were 45.3% vs 39.5%, respectively. Importantly, response rates in the elderly population aged ≥70 years did not tend to be inferior to those in the younger population aged <70 years.
| Survival
Survival analysis was performed for 500 patients after excluding 23 patients lost to follow-up from the effectiveness analysis population of 523 patients. Events, any death, were observed in 260 (55.0%) out 
| Univariate and multivariate analyses of prognostic factors
A correlation analysis confirmed that there were no mutual correlations between the sets of variables (data not shown), that is, patients aged ≥70 years were not prone to have poorer PS and more unfavorable laboratory results than patients aged <70 years, and no association existed between survival time and age as a continuous variable (data not shown).
As shown in 
| D ISCUSS I ON
The safety profile reported in this surveillance study was similar to that reported in our preliminary report 12 and in previous clinical trials. 10, 11, 15 IRRs, skin disorders, and infections which were collected as mandatory items were the most common ADRs, and the frequencies for the first two events were less than those reported in the clinical study of patients with relapsed ATL using the same administration schedule of mogamulizumab as used in this surveillance.
11
Less frequent IRRs may be attributed to differences in the monitoring system between the clinical surveillance studies, use of corticosteroids as premedication and antiemetics, and combination with corticosteroid-containing chemotherapy in this surveillance study.
Skin disorders are one of the characteristic toxicities of mogamuli-
zumab. An exploratory analysis to determine factors inducing skin However, except for the number of mogamulizumab infusion described in the previous report, 12 the other factors were not reliable predictors of skin disorders. Skin disorders were late-onset toxicities with a median time to onset of 35.5 days and a maximum time to onset of 230 days. Hence, patients should be monitored carefully not only during mogamulizumab therapy but also after completion of the therapy. In phase 1 and 2 studies of mogamulizumab monotherapy, 10, 11, 16 CMV infection or viremia, pneumonia, and sepsis were reported in 2.5%, 1.3%, and none of the patients, respectively, while in this surveillance, the incidence was relatively higher (8.2%, 4.0%, and 2.3% of patients, respectively). The differences in incidences may be partly due to the inclusion of patients with longer follow-up time, poor condition or patients who received combination therapy in this surveillance. The incidences of overall and serious ADRs were similar between patients aged ≥70 and <70 years in this surveillance.
The best response rate and response rate at the end of therapy were 57.9% and 42.0%, respectively, indicating that, of the 57.9%
of responders, approximately 30% experienced disease progression during treatment. To identify the risk factors for such early progression should be future clinical question. Mogamulizumab also showed similar response rates in both patients aged ≥70 and <70 years in this surveillance as well the other approved therapeutic monoclonal antibodies.
17,18
The median OS in our surveillance was 5.5 months, which was much shorter than the 13.7 months reported in the phase 2 study of mogamulizumab in patients with relapsed ATL. and might be higher compared with that of HSCT not preceded by mogamulizumab, suggesting the risk of severe GVHD is increased by administering mogamulizumab before allogeneic HSCT in patients with ATL. 12 However, it should be paid attention to be led by a small number of patients who have many background factors. According to our multivariate analysis, poor PS of 2-4, low serum albumin <3.5 g/dL, high corrected serum calcium ≥2.75 mmol/L, and high LDH >240 IU/L were associated with poor prognosis, with P < 0.05 or of borderline significance. These results were consistent with those of previous publications. 3, 13, 14 However, age was not associated with survival in this surveillance, contradictory to previous reports using cut-off ages of ≤70 and >70 years. 13 This could be due to the influence of other factors not assessed here. Other studies having small sample sizes, 23, 24 which performed univariate analysis for the mogamulizumab-treated population with r/r ATL, have also reported that age >65 or ≥70 years was not associated with poor prognosis.
TA B L E 4 Prognostic factors
As previously reported, 12 due to the nature of surveillance, data collection for safety was considered to be less frequent and response assessment less objective since they were assessed by an attending physician during clinical practice. Additionally, our observation period, at the longest of 31 weeks from the first dosing of mogamulizumab, might not be sufficiently long to evaluate OS and analyze prognostic factors even though the events occurred in 55% of patients during this period. Despite these limitations, the surveillance, which prospectively enrolled more than 500 patients with rare disease (r/r ATL), is valuable for future treatment development.
In conclusion, in clinical practice, the overall safety profile of mogamulizumab was manageable in most patients and was consistent with previous reports. The best response rate was reported to be over 50% and the median survival was 5.5 months. The safety profile, response, and survival were not different between patients aged ≥70 and <70 years, and age was not associated with prognosis.
In clinical practice, mogamulizumab therapy was confirmed to be a feasible option for the treatment of patients with r/r ATL, including the elderly.
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